{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse Events of Special Interest (whether serious or non serious) were collected.","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG002","title":"2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"Up to approximately 281 weeks.","title":"DE Phase: Number of Participants With Adverse Events of Special Interest (AESI)","type":"SECONDARY","unitOfMeasure":"Participants"}